This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Leventhal, J. et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4, 124ra128 (2012).
Ildstad, S.T. & Sachs, D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307, 168–170 (1984).
Fudaba, Y. et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6, 2121–2133 (2006).
Scandling, J.D. et al. Induced immune tolerance for kidney transplantation. N. Engl. J. Med. 365, 1359–1360 (2011).
Kawai, T. et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353–361 (2008).
Newell, K.A. et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836–1847 (2010).
Sagoo, P. et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120, 1848–1861 (2010).
Vallera, D.A., Youle, R.J., Neville, D.M. Jr. & Kersey, J.H. Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti–Thy-1.2 coupled to the toxin ricin. J. Exp. Med. 155, 949–954 (1982).
Cobbold, S.P., Martin, G., Qin, S. & Waldmann, H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 323, 164–166 (1986).
Bemelman, F., Honey, K., Adams, E., Cobbold, S. & Waldmann, H. Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose. J. Immunol. 160, 2645–2648 (1998).
Brunstein, C.G. et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118, 282–288 (2011).
Ethics declarations
Competing interests
L.A.T.'s wife is an employee of Novartis, and the two of them own stock in the company. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
A step closer to effective transplant tolerance?. Nat Med 18, 664–665 (2012). https://doi.org/10.1038/nm.2770
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2770